Press Release Archive

Archives:

  2017 / 2016 / 2015 / 2014 / 2013

Tuesday, December 13, 2016

Harrington Discovery Institute at University Hospitals announces inaugural class of Cleveland Harrington Fellows

CLEVELAND – 2016 Harrington Fellows have been selected by Harrington Discovery Institute. The new Harrington Fellows Award recognizes promising early- to mid-career physician-scientists in the greater Cleveland medical community and provides $75,000 per year for two years to support their research efforts.
 
Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling the nation’s most inventive physician-scientists to turn their discoveries into medicines that improve human health.
 
The 2016 Harrington Fellows are:

Derek Abbott, MD, PhD, Associate Professor and Arline H. and Curtis F. Garvin Professor of Medicine and Co-Director, Medical Scientist Training Program, Case Western Reserve University School of Medicine. Dr. Abbott’s research has combined molecular, bioinformatics and proteomic approaches to identify and pharmaceutically target novel inflammatory signaling pathways. 

Alex Huang, MD, PhD, Associate Professor, Case Western Reserve University School of Medicine and Program Director, Pediatric Hematology and Oncology, UH Cleveland Medical Center. Dr. Huang’s research is focused on understanding cancer immunology and defining the cellular and molecular immunological principles governing tumor immunity to advance the application of cancer immunotherapy.

Nima Sharifi, MD, Kendrick Family Endowed Chair for Prostate Cancer Research, Cleveland Clinic Lerner Research Institute and Co-Director of the Prostate Cancer Research Center of Excellence at Cleveland Clinic. Dr. Sharifi’s research is centered on investigating metabolic and molecular mechanisms of hormone therapy resistance in prostate cancer and the development of new treatment strategies.
 
“We are pleased to support the research efforts of these three talented physician-scientists,” said Jonathan Stamler, MD, President of Harrington Discovery Institute, who also is Director of the Institute for Transformative Molecular Medicine at Case Western Reserve University School of Medicine. “These physician-scientists are driven by their commitment to patients for whom they have cared and we are committed to ensuring that our community can benefit from its creative talent.” 


Friday, December 09, 2016

UH Seidman Cancer Center expert to present novel Triple-Negative Breast Cancer immunotherapy trial at 2016 San Antonio Breast Cancer Symposium

CLEVELAND – A researcher from University Hospitals Seidman Cancer Center will discuss his upcoming immunotherapy clinical trial for triple-negative breast cancer at the 2016 San Antonio Breast Cancer Symposium. The annual symposium is the premier meeting for more than 7,500 physicians and scientists dedicated to breast cancer treatment, featuring state-of-the-art breast cancer research such as experimental biology, etiology, prevention, diagnosis, and therapy of both breast cancer and premalignant breast disease.  
 
Joseph Baar, MD, PhD, Director of Breast Cancer Research at UH Seidman Cancer Center and Associate Professor at Case Western Reserve University School of Medicine, will share details about a phase II clinical trial testing the effectiveness of combining the chemotherapy drugs carboplatin and nab-paclitaxel with an immunotherapeutic agent called pembrolizumab (Keytruda) for use in patients with metastatic triple-negative breast cancer. Dr. Baar’s poster presentation will be part of the Ongoing Trials-Targeted Therapy session on December 8, 2016 from 5 pm to 7 pm.
 
“Up until now, women with triple-negative breast cancer have only had one treatment option, which is chemotherapy. However, more recently, we’ve seen that the immune modulator pembrolizumab improves outcomes in patients with metastatic triple-negative breast cancer,” said Dr. Baar. “As a result, it is now critical to explore how the addition of pembrolizumab to chemotherapy might improve  survival in patients with this type of breast cancer.”


Monday, December 05, 2016

Advances in Multiple Myeloma, Lymphoma and other Hematologic Malignancies Presented at Annual Meeting of American Society of Hematology

CLEVELAND – Researchers from University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine presented significant new research findings in multiple myeloma, lymphoma and other hematologic disorders at the 58th Annual Meeting of American Society of Hematology (ASH) in San Diego.  
 
“The breadth and depth of this innovative cancer research presented at ASH is truly outstanding,” says Stan Gerson, MD, Director of UH Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve. “Our faculty members are making tremendous advances in multiple myeloma, lymphoma and other hematologic malignancies which is reflected in their being selected for oral and poster presentations.”
 
Major advances have been made in treating multiple myeloma (MM) over the last 12 years and early phase clinical trials have played a key role in this progress according to an oral presentation (Abstract #1146) by Ehsan Malek, MD, of UH Seidman Cancer Center. Phase I trials, in addition to moving progress forward for new treatments, also have demonstrated therapeutic success for patients and are well tolerated.


Saturday, December 03, 2016

UH Rainbow Babies & Children’s Hospital Experts to Present Pediatric Focused Data at 58th American Society of Hematology Annual Meeting

CLEVELAND – Researchers from the Angie Fowler Adolescent & Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children’s Hospital (UH Rainbow) will present data focused on improving clinical outcomes for pediatric hematologic disorders at the 58th Annual Meeting of the American Society of Hematology (ASH). The meeting, held from December 3 to 6, 2016, in San Diego, California, gathers a global community of more than 20,000 hematologists to share education and research on the most pressing topics in hematology.
 
Ashish Gupta, MBBS, MPH, a pediatric hematology fellow at UH Rainbow, will share results from one of the largest quality controlled retrospective studies of children with acquired aplastic anemia. The data makes a compelling case for the pediatric hematology community to revisit the current treatment algorithm for this rare disease. 


Tuesday, November 15, 2016

Non-profit organization Babies Need Boxes expands to Ohio

CLEVELAND – University Hospitals (UH) MacDonald Women’s Hospital is collaborating with non-profit organization Babies Need Boxes Ohio to provide a free maternity package for expectant mothers that includes a safe sleep space for baby. The program will launch Tuesday, Nov. 15, at 11 a.m. at UH MacDonald Women’s Hospital’s CenteringPregnancy session.
 
“There are nearly 200 cases of sudden, unexplained infant deaths in Ohio each year, and research tells us two of the biggest contributors are premature birth and unsafe sleep arrangements,” says Celina Cunanan, CNM, MSN, Director of Nurse-Midwifery at UH MacDonald Women’s Hospital and founding board member of Babies Need Boxes Ohio. “Babies Need Boxes will help us fill a gap in the availability of safe sleep spaces for our pregnant moms to help keep their sleeping newborn safe.”
 
Babies Need Boxes was founded in 2015 by Danielle Selassie after she read an article about the impact baby boxes had in Finland to decrease the nation’s infant mortality rate. The Minnesota-based organization equips families with tangible resources to help ease the transition to parenthood and prevent Sudden Infant Death Syndrome (SIDS). 



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.